<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01354171</url>
  </required_header>
  <id_info>
    <org_study_id>CURC-003</org_study_id>
    <nct_id>NCT01354171</nct_id>
  </id_info>
  <brief_title>Active Surveillance Magnetic Resonance Imaging Study</brief_title>
  <acronym>ASIST</acronym>
  <official_title>Active Surveillance Magnetic Resonance Imaging Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Urology Research Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>OICR</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eigen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Urology Research Consortium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-centre, prospective, randomized phase III trial to determine if
      multi-parametric Magnetic Resonance Imaging (MRI) can improve selection of patients eligible
      for active surveillance through better detection of clinically significant cancer.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the proportion of subjects whose confirmatory biopsy is upgraded to Gleason score 7 (3+4) or higher</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the proportion of subjects whose confirmatory biopsy is upgraded to Gleason score 7 (4 + 3) or higher</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>TRUS guided biopsy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MRI Assisted TRUS guided biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI assisted TRUS guided biopsy</intervention_name>
    <description>All subjects to have a confirmatory biopsy at one year. Those assigned ARM 1 to have a TRUS guided biopsy and those assigned to ARM 2to have a MRI assisted TRUS guided biopsy</description>
    <arm_group_label>MRI Assisted TRUS guided biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histological confirmation of adenocarcinoma of the prostate

          -  candidate for active surveillance (favourable risk prostate cancer) as defined by the
             following:

               -  Clinical stage T1b, T1c, T2a or T2b at the time of diagnosis

               -  Clinical (diagnostic biopsy) Gleason sum &lt; 6

               -  PSA &lt; 10.0 ng/ml (ug/L)

        Exclusion Criteria:

          -  Previous treatment for prostate cancer including surgery (excluding biopsy), radiation
             therapy, hormonal therapy (e.g. megestrol, medroxyprogesterone, cyproterone, DES),
             glucocorticoids (except inhaled or topical), LHRH analogues (e.g. Leuprolide,
             goserelin), ketoconazole, non-steroidal antiandrogens (e.g. bicalutamide, flutamide)
             and/or any 5Î±-reductase inhibitors within 3 months of randomization

          -  Planned anti-androgen therapy

          -  Inability to undergo TRUS biopsy

          -  Inability to undergo multi-parametric MRI
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurence Klotz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Canadian Urology Research Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2011</study_first_submitted>
  <study_first_submitted_qc>May 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2011</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>active surveillance</keyword>
  <keyword>low risk prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

